CapsoVision, Inc. completed its initial public offering (IPO), raising $27.5 million before underwriting discounts and commissions. The company sold 5.5 million shares at $5.00 each. Trading under the ticker “CV,” shares began on the Nasdaq Capital Market on July 2, 2025.
Current Share Price:
What Is Small Bowel Endoscopy?
Small bowel endoscopy is a procedure used to examine the small intestine, a long and narrow part of the digestive tract that plays a crucial role in nutrient absorption. Traditional methods to view this area, such as enteroscopy, can be invasive, require sedation and demand specialized equipment and expertise.
CapsoVision IPO and Technologies Overview
CapsoVision develops advanced imaging and AI solutions for gastrointestinal (GI) diagnostics. Its capsule endoscopy products capture panoramic, high-resolution images as they pass through the digestive tract, in a way that is less invasive and more comfortable for patients, thus simplifying clinical workflows by eliminating patient-worn data recorders.
Its flagship product, CapsoCam Plus, which has been cleared by the FDA for small bowel visualization, features four cameras, offering a 360-degree panoramic view of the small bowel mucosa.
CapsoCam Plus is a wire-free, telemedicine-enabled system that stores video internally, allowing patients to ingest the capsule at home under remote provider supervision. As a cloud-based platform, it enables clinicians to track procedures and review videos, improving workflow and patient convenience. This supports the detection of conditions like obscure GI bleeding and Crohn’s disease.
CapsoVision is developing CapsoCam Colon for non-invasive colon imaging and polyp detection. It integrates AI to automatically identify polyps and uses a 3D sensor to measure polyp size, a key cancer risk factor. The company submitted its 510(k) application in June 2025, aiming to commercialize in the US by late 2026, with European approvals planned.
CapsoVision has grown steadily. Company revenues reached $11.8 million in 2024, up 21% year-over-year. Over 135,000 patients worldwide have used the small bowel capsule, with a 90% customer retention rate in 2024.
The company is also advancing AI-assisted reading tools that highlight suspected abnormalities to reduce clinician review time. It aims to secure FDA and European Union (EU) clearance for these features by the end of 2025. Expanded indications for CapsoCam Plus include pediatric use and telemedicine supervision.
CapsoVision is also developing a capsule delivery device for patients who are unable to swallow capsules and a patency capsule to ensure safe passage in patients with GI strictures.
Looking ahead, feasibility studies are planned to evaluate CapsoCam’s accuracy in screening esophageal varices in cirrhotic patients and detecting precancerous pancreatic abnormalities.
Advances in AI-Assisted Gastroenterology Care
CapsoVision enters a space where AI innovation has been making strides for a while now. Let’s look at some products over the years exemplifying this trend:
- AnX Robotica (May 2025): AnX Robotica’s MotiliCap and MotiliScan, cleared this year, are a next-gen motility capsule and software that assess GI transit across the stomach, small bowel and colon without radiation or sedation. The system provides detailed insights into motility patterns by measuring pH, pressure and temperature.
- Seoreu (CES 2025): This South Korea-based company unveiled the CAPTOS capsule in Jan 2025, which uses AI to automatically analyze GI tract images. It highlights suspicious areas such as inflammation or lesions, reducing clinicians’ video review time and accelerating diagnosis.
- G-Tech Medical (2022): The FDA-approved Gastrointestinal Motility Monitoring System leverages AI to track and interpret digestive tract muscle contractions and movement patterns, aiding diagnosis of motility disorders like gastroparesis or chronic constipation.
- Medtronic (2021): The PillCam system was cleared for home use, employing AI-powered video analysis to automatically flag potential abnormalities in the small bowel, enabling remote patient procedures with improved convenience.
As AI advances and gains approvals, it may become a standard part of GI diagnostics and patient care.
If you want your company to be featured on Xtalks.com, please email [email protected].
Join or login to leave a comment
JOIN LOGIN